- In February 2023, Aldeyra Therapeutics, Inc. announced the commencement of Phase 2 clinical trials to assess the safety and efficacy of ADX-629, an innovative oral RASP modulator developed in-house. This investigational treatment targets both minimal change disease and Sjogren-Larsson Syndrome. Additionally, Aldeyra revealed plans to expand the minimal change disease trial to include idiopathic nephrotic syndrome, which encompasses a range of rare, immune-mediated kidney disorders, further broadening the scope of their research
- In November 2022, Alembic Pharmaceuticals obtained final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Cyclophosphamide Capsules, available in 25 mg and 50 mg dosages. This approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Cyclophosphamide Capsules, produced by Hikma Pharmaceuticals USA Inc. Cyclophosphamide is an alkylating agent indicated for treating malignant diseases as well as minimal change nephrotic syndrome in pediatric patients, highlighting its significance in pediatric nephrology
Frequently Asked Questions
The market is segmented based on Segmentation, By Drugs (Sodium Restriction Drugs, Fluid Restriction Drugs, Loop Diuretics, Angiotensin-Converting Enzyme Inhibitor (or Angiotensin Receptor Blocker Therapy), and Others), Diagnosis Tests (Urinalysis, Glomerular Filtration Rate (GFR), Blood Test, Kidney Biopsy, and Computerized Tomography (CT) Scan), End-Users (Clinics, Hospitals, Speciality Centres, and Others) – Industry Trends and Forecast to 2032
.
The Global Nephrotic Syndrome Market size was valued at USD 952.93 USD Million in 2024.
The Global Nephrotic Syndrome Market is projected to grow at a CAGR of 10.7% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
